Carlos Andrés Vergara Sánchez: AI-Driven CCTA Plaque Quantification for Better ASCVD Risk Assessment
Carlos Andrés Vergara Sánchez, Chief Cardiovascular Disease Fellow at Mayo Clinic College of Medicine and Science, shared a post on LinkedIn, about a recent article by Shyon Parsa et al, adding:
“New insights on ASCVD risk stratification using AI‑enabled CCTA plaque quantification.
A recent study by S. Parsa et al. explores an important question:
Can AI‑derived plaque quantification from CCTA guide lipid‑lowering therapy and individualize ASCVD prevention?
Their findings suggest the answer may be yes.
Study Overview
- 6,054 adults from the FISH and CHIPS observational study
- Conducted across two UK clinical sites
- Underwent clinically indicated CCTA with AI plaque quantification in symptomatic patients
- Total plaque volume (TPV) categorized into four DECIDE stages (1–4), which were then linked to LDL‑C targets for a ‘treat‑to‑target’ strategy.
LDL‑C Targets by DECIDE Stage
- Stage 1: LDL‑C less than 100 mg/dL
- Stage 2: LDL‑C less than 70 mg/dL
- Stage 3: LDL‑C less than 55 mg/dL
- Stage 4: LDL‑C less than 40 mg/dL
(Usual care LDL‑C approximately 100 mg/dL)
Key Findings
10‑year Relative Risk Reduction in MACE
- Stage 1: 1.47 percent
- Stage 2: 18.15 percent
- Stage 3: 24.24 percent
- Stage 4: 33.76 percent
10‑year Number Needed to Treat (NNT)
- Stage 1: 1686
- Stage 2: 59
- Stage 3: 27
- Stage 4: 11
Across the full cohort:
- 19.12 percent risk reduction
- NNT of 61
- Importantly, the NNT continued improving at 3‑, 5‑, and 10‑year follow‑ups.
Why This Matters
This AI‑enabled, plaque‑guided strategy could potentially:
- Improve cardiovascular outcomes
- Identify high‑risk patients who would benefit from therapy intensification
- Move prevention toward a more individualized, imaging‑driven paradigm.
This is a very important work in the new era of AI-driven care.
As we try to find different ways to optimize and personalize prevention strategies before we manage the consequences of atherosclerosis, whether there is presence of events or not.
Translating the use of standardized AI based plaque analysis technology into tangible outcomes, gives more of a base for clinicians to decide whether it is worth and cost effective to go beyond CAC score given the current technology, and its continued advancement.
Where does this leave us?
Cardiovascular disease prevention is in an era where we have more tools for every aspect.
AI is here to stay and implementing it efficiently in our clinical practice will help us more than ever to capture more patients that would benefit from our expanding arsenal of therapies, earlier and more aggressively.
AI plaque analysis is a promising technology already showing results, the cost of implementation will be an issue, and to adapt to a new paradigm, more data is needed, fast.
Something is clear, the evidence of ‘lower is better’ when it comes to atherogenic lipoproteins (i.e. LDL) continues to be supported with every study.
This is a study worth reading carefully.”
Title: Artificial intelligence-enabled coronary plaque quantification for personalized risk assessment and lipid-lowering therapy: Insights from the FISH and CHIPS study
Authors: Shyon Parsa, Allison W. Peng, Jack Bell, Souma Sengupta, Sarah Mullen, Campbell Rogers, Edward D Nicol, Jonathan R Weir-McCall, Laurence Tidbury, Seth S. Martin, Timothy Fairbairn, Fatima Rodriguez
Read the Full Article on American Journal of Preventive Cardiology
Read the Editorial.
Stay updated with Hemostasis Today.
-
Oct 30, 2026, 05:18Flora Peyvandi: Molecular and Lab Markers Linked to Bleeding Severity in Factor VII Deficiency
-
Oct 30, 2026, 05:11Rana Al-Hrout: Exploring Approach to Macrocytic Anemia
-
Oct 30, 2026, 04:22Francisco Chacón-Lozsán: Acute Pulmonary Embolism in 2026 – Blood Pressure Is Not the Same as Perfusion
-
Oct 30, 2026, 04:15Samin Mohsenian: Launching the PRO-RBDD-FX Registry for Rare Coagulation Factor X Deficiency
-
Oct 30, 2026, 03:59Emil List Larsen: Identifying SERPINC1 Variants and Limitations of Routine Antithrombin Testing
-
Oct 30, 2026, 02:43D Chandra: Reduce the Apixaban Dose for a Patient with VTE and a Creatinine Clearance of 25?
-
Oct 30, 2026, 02:38Spencer Dorn: Why AI Decision Support Must Integrate Local Clinical Context
-
Oct 30, 2026, 02:33Jens Eschen: Randomized Controlled Trial on Acute Aortic Dissection Anticoagulation Strategies
-
Oct 30, 2026, 02:23Mavis Agnes Kisakye: Landmark Study Paves the Way for Standardized Bleeding Disorder Guidelines in Uganda